Ocera Therapeutics, Inc.
OCRX
OCRX was delisted on the 8th of December, 2017.
26 hedge funds and large institutions have $7.22M invested in Ocera Therapeutics, Inc. in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 2 reducing their positions, and 16 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 2
16.2% less ownership
Funds ownership: 39.57% → 23.37% (-16%)
28% less funds holding
Funds holding: 36 → 26 (-10)
44% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 16
62% less capital invested
Capital invested by funds: $19.2M → $7.22M (-$12M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$2.74M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.15M |
| 3 |
HP
Hikari Power
Tokyo,
Japan
|
+$318K |
| 4 |
BlackRock
New York
|
+$79.4K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$70.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.12M |
| 2 |
IVM
InterWest Venture Management
San Francisco,
California
|
-$2.62M |
| 3 |
QF
QVT Financial
New York
|
-$1.9M |
| 4 |
DM
Deerfield Management
New York
|
-$1.2M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$690K |
OCRX Hedge Fund Activity: Q1 2017 in Review
26 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Ocera Therapeutics, Inc. (OCRX) for Q1 2017, worth a combined $7.22M — down 62% from $19.2M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of OCRX and 9 opened new positions — a net loss of 7 holders — while 2 trimmed existing stakes and 10 added.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $2.74M. The largest seller was Great Point Partners, exiting entirely with an estimated $4.12M sold.
- 26 institutional investors held Ocera Therapeutics, Inc. (OCRX) as of Q1 2017, down from 36 in Q4 2016.
- Funds reported $7.22M of Ocera Therapeutics, Inc. stock for Q1 2017, down 62% quarter-over-quarter.
- 9 funds opened new Ocera Therapeutics, Inc. positions in Q1 2017 and 16 closed out, a net change of -7 holders.
- The largest Ocera Therapeutics, Inc. buyer in Q1 2017 was Perceptive Advisors, an estimated $2.74M added.
- The largest Ocera Therapeutics, Inc. seller in Q1 2017 was Great Point Partners, an estimated $4.12M sold.
Based on aggregated 13F filings for Q1 2017.